共找到 20 条结果
Pharmacovigilance systems handle sensitive healthcare and drug-safety data, including adverse event reports and clinical observations. As quantum computing advances, classical public-key cryptographic systems such as RSA and elliptic-curve cryptography may become vulnerable, creating long-term risks for healthcare data that must remain confidential for many years. This paper presents an educational prototype of a post-quantum secure pharmacovigilance data pipeline. The system uses ML-KEM-768 for post-quantum key establishment, HKDF-SHA-256 for deriving an AES key, AES-256-GCM for efficient file encryption, and ML-DSA-65 for digital signatures and tamper detection. The pipeline supports multiple file formats, including TXT, CSV, JSON, and PDF, by treating files as raw bytes and preserving metadata for reconstruction at the receiver. The prototype includes separate hospital, gateway, pharma receiver, attacker, benchmarking, and dashboard components. We evaluate the system using synthetic pharmacovigilance datasets of different sizes and formats. Our results show that ML-KEM adds a small constant overhead, while AES encryption and ML-DSA signing dominate runtime as file size increases
We present \textbf{EGPF} (Equilibrium-Guided Personalization Framework), a mathematically rigorous architecture unifying Bayesian game theory, category theory, information theory, and generative AI for hyper-personalized physician engagement in the pharmaceutical domain. Our framework models the pharma--physician interaction as an incomplete-information Bayesian game where physician behavioral types are inferred via functorial mappings from observational categories, equilibrium strategies guide content generation through large language models (LLMs), and information-theoretic feedback loops ensure adaptive recalibration. We formalize behavior composition through category-theoretic functors, natural transformations, and monoidal structures, enabling modular, composable physician archetypes that respect structural invariants under domain shift. We introduce a novel \textit{Rate-Distortion Equilibrium} (RDE) criterion that bounds the personalization--privacy tradeoff, an \textit{Evolutionary Game Dynamics} layer for population-level behavior modeling, a \textit{Mechanism Design} module for incentive-compatible engagement, and a \textit{Sheaf-Theoretic} extension for multi-scale behavi
We present a Japanese domain-specific language model for the pharmaceutical field, developed through continual pretraining on 2 billion Japanese pharmaceutical tokens and 8 billion English biomedical tokens. To enable rigorous evaluation, we introduce three new benchmarks: YakugakuQA, based on national pharmacist licensing exams; NayoseQA, which tests cross-lingual synonym and terminology normalization; and SogoCheck, a novel task designed to assess consistency reasoning between paired statements. We evaluate our model against both open-source medical LLMs and commercial models, including GPT-4o. Results show that our domain-specific model outperforms existing open models and achieves competitive performance with commercial ones, particularly on terminology-heavy and knowledge-based tasks. Interestingly, even GPT-4o performs poorly on SogoCheck, suggesting that cross-sentence consistency reasoning remains an open challenge. Our benchmark suite offers a broader diagnostic lens for pharmaceutical NLP, covering factual recall, lexical variation, and logical consistency. This work demonstrates the feasibility of building practical, secure, and cost-effective language models for Japanes
The discovery of novel small molecule drugs remains a critical scientific challenge with far-reaching implications for treating diseases and advancing human health. Traditional drug development--especially for small molecule therapeutics--is a highly complex, resource-intensive, and time-consuming process that requires multidisciplinary collaboration. Recent breakthroughs in artificial intelligence (AI), particularly the rise of large language models (LLMs), present a transformative opportunity to streamline and accelerate this process. In this paper, we introduce PharmAgents, a virtual pharmaceutical ecosystem driven by LLM-based multi-agent collaboration. PharmAgents simulates the full drug discovery workflow--from target discovery to preclinical evaluation--by integrating explainable, LLM-driven agents equipped with specialized machine learning models and computational tools. Through structured knowledge exchange and automated optimization, PharmAgents identifies potential therapeutic targets, discovers promising lead compounds, enhances binding affinity and key molecular properties, and performs in silico analyses of toxicity and synthetic feasibility. Additionally, the system
General-purpose LLMs with web search are increasingly used to scout the competitive landscape of pharmaceutical pipelines. We benchmark Gosset -- an AI platform with a chat interface backed by curated target-, modality-, and indication-level drug-asset annotations -- against four frontier systems with web access (Claude Opus 4.7, GPT 5.5, Gemini 3.1 Pro, Perplexity sonar-pro) on ten niche oncology/immunology targets where most of the pipeline lives in the long tail of preclinical and Asian-developed assets. All five systems receive the same natural-language query and the same JSON output schema. Across 10 targets Gosset returns 3.2x more verified drugs per query than the best frontier system, at perfect precision and 100% recall against the cross-system union of verified drugs. The same curated index is exposed as a Gosset MCP server that any frontier model can call as a tool, suggesting that each of these systems can close most of the recall gap by swapping generic web search for a curated index behind the same chat interface.
This paper introduces a reinforcement learning (RL) platform that enhances end-to-end user journeys in healthcare digital tools through personalization. We explore a case study with SwipeRx, the most popular all-in-one app for pharmacists in Southeast Asia, demonstrating how the platform can be used to personalize and adapt user experiences. Our RL framework is tested through a series of experiments with product recommendations tailored to each pharmacy based on real-time information on their purchasing history and in-app engagement, showing a significant increase in basket size. By integrating adaptive interventions into existing mobile health solutions and enriching user journeys, our platform offers a scalable solution to improve pharmaceutical supply chain management, health worker capacity building, and clinical decision and patient care, ultimately contributing to better healthcare outcomes.
This document offers a critical overview of the emerging trends and significant advancements in artificial intelligence (AI) within the pharmaceutical industry. Detailing its application across key operational areas, including research and development, animal testing, clinical trials, hospital clinical stages, production, regulatory affairs, quality control and other supporting areas, the paper categorically examines AI's role in each sector. Special emphasis is placed on cutting-edge AI technologies like machine learning algorithms and their contributions to various aspects of pharmaceutical operations. Through this comprehensive analysis, the paper highlights the transformative potential of AI in reshaping the pharmaceutical industry's future.
In the pharmaceutical industry, the use of artificial intelligence (AI) has seen consistent growth over the past decade. This rise is attributed to major advancements in statistical machine learning methodologies, computational capabilities and the increased availability of large datasets. AI techniques are applied throughout different stages of drug development, ranging from drug discovery to post-marketing benefit-risk assessment. Kolluri et al. provided a review of several case studies that span these stages, featuring key applications such as protein structure prediction, success probability estimation, subgroup identification, and AI-assisted clinical trial monitoring. From a regulatory standpoint, there was a notable uptick in submissions incorporating AI components in 2021. The most prevalent therapeutic areas leveraging AI were oncology (27%), psychiatry (15%), gastroenterology (12%), and neurology (11%). The paradigm of personalized or precision medicine has gained significant traction in recent research, partly due to advancements in AI techniques \cite{hamburg2010path}. This shift has had a transformative impact on the pharmaceutical industry. Departing from the traditio
The rapid advance of generative AI is reshaping the strategic vision for R&D across industries. The unique challenges of pharmaceutical R&D will see applications of generative AI deliver value along the entire value chain from early discovery to regulatory approval. This perspective reviews these challenges and takes a three-horizon approach to explore the generative AI applications already delivering impact, the disruptive opportunities which are just around the corner, and the longer-term transformation which will shape the future of the industry. Selected applications are reviewed for their potential to drive increase productivity, accelerate timelines, improve the quality of research, data and decision making, and support a sustainable future for the industry. Recommendations are given for Pharma R&D leaders developing a generative AI strategy today which will lay the groundwork for getting real value from the technology and safeguarding future growth. Generative AI is today providing new, efficient routes to accessing and combining organisational data to drive productivity. Next, this impact will reach clinical development, enhancing the patient experience, driving
Pharmaceutical companies operate in a strictly regulated and highly risky environment in which a single slip can lead to serious financial implications. Accordingly, the announcements of clinical trial results tend to determine the future course of events, hence being closely monitored by the public. In this work, we provide statistical evidence for the result promulgation influence on the public pharma market value. Whereas most works focus on retrospective impact analysis, the present research aims to predict the numerical values of announcement-induced changes in stock prices. For this purpose, we develop a pipeline that includes a BERT-based model for extracting sentiment polarity of announcements, a Temporal Fusion Transformer for forecasting the expected return, a graph convolution network for capturing event relationships, and gradient boosting for predicting the price change. The challenge of the problem lies in inherently different patterns of responses to positive and negative announcements, reflected in a stronger and more pronounced reaction to the negative news. Moreover, such phenomenon as the drop in stocks after the positive announcements affirms the counterintuitiv
There is a widespread perception that pharmaceutical R&D is facing a productivity crisis characterised by stagnation in the numbers of new drug approvals in the face of increasing R&D costs. This study explores pharmaceutical R&D dynamics by examining the publication activities of all R&D laboratories of the major European and US pharmaceutical firms during the period 1995-2009. The empirical findings present an industry in transformation.In the first place, we observe a decline of the total number of publications by large firms. Second, we show a relative increase of their external collaborations suggesting a tendency to outsource, and a diversification of the disciplinary base, in particular towards computation, health services and more clinical approaches. Also evident is a more pronounced decline in publications by both R&D laboratories located in Europe and by firms with European headquarters. Finally, while publications by Big Pharma in emerging economies sharply increase, they remain extremely low compared with those in developed countries. In summary, the trend in this transformation is one of a gradual decrease in internal research efforts and increasin
Quantum computers are special purpose machines that are expected to be particularly useful in simulating strongly correlated chemical systems. The quantum computer excels at treating a moderate number of orbitals within an active space in a fully quantum mechanical manner. We present a quantum phase estimation calculation on F$_2$ in a (2,2) active space on Rigetti's Aspen-11 QPU. While this is a promising start, it also underlines the need for carefully selecting the orbital spaces treated by the quantum computer. In this work, a scheme for selecting such an active space automatically is described and simulated results obtained using both the quantum phase estimation (QPE) and variational quantum eigensolver (VQE) algorithms are presented and combined with a subtractive method to enable accurate description of the environment. The active occupied space is selected from orbitals localized on the chemically relevant fragment of the molecule, while the corresponding virtual space is chosen based on the magnitude of interactions with the occupied space calculated from perturbation theory. This protocol is then applied to two chemical systems of pharmaceutical relevance: the enzyme [Fe
Agentic systems for drug discovery have demonstrated autonomous synthesis planning, literature mining, and molecular design. We ask how well they generalize. Evaluating six frameworks against 15 task classes drawn from peptide therapeutics, in vivo pharmacology, and resource-constrained settings, we find five capability gaps: no support for protein language models or peptide-specific prediction, no bridges between in vivo and in silico data, reliance on LLM inference with no pathway to ML training or reinforcement learning, assumptions tied to large-pharma resources, and single-objective optimization that ignores safety-efficacy-stability trade-offs. A paired knowledge-probing experiment suggests the bottleneck is architectural rather than epistemic: four frontier LLMs reason about peptides at levels comparable to small molecules, yet no framework exposes this capability. We propose design requirements and a capability matrix for next-generation frameworks that function as computational partners under realistic constraints.
LLarge language model (LLM)-based AI agents deployed in manufacturing environments require populated, schema-correct data for validation, yet production MES data is proprietary, privacy-encumbered, and vendor-specific. This paper introduces the Template-as-Ontology principle: a single Python configuration module (700-770 lines, 45 validated exports) serves simultaneously as the specification for a time-stepped manufacturing simulator and as the runtime domain schema for AI analytics tools, producing alignment by construction rather than integration. We formally define the domain template as a typed relational configuration schema and prove that structural alignment between simulation and tool layers is guaranteed by single-source consumption. A five-layer pipeline--simulation, PostgreSQL, CDC/Iceberg lakehouse, star schema, and 12 parameterized AI tools--generates causally coherent, MES-shaped data spanning 66 entity types across four operational domains mapped to ISA-95/IEC 62264. We validate the architecture with six industry templates (aerospace, pharma, automotive, electronics, beverages, warehousing) running on identical framework code. Calibration experiments (60 runs, 10 see
Pharmaceutical drug discovery demands machine learning (ML) infrastructure that goes beyond general-purpose Machine Learning Operations (MLOps): inference-time composition of multiple models for multi-parameter optimization (MPO), version management for physics-based models without serialized ML artifacts, enterprise compound library precomputation, and governance structured around scientific organizational units rather than generic access controls. No existing commercial or open-source platform simultaneously addresses this full set of requirements. This paper presents the Model Gateway, a cloud-based platform for managing machine learning and scientific computational models across drug discovery pipelines, providing centralized version control, pharma-structured governance, asynchronous execution, consensus model orchestration, automated retraining, and a unified application programming interface (API) service for heterogeneous clients including molecular design suites and Large Language Model (LLM) agents. In production at Eli Lilly, the platform governs more than 200 deployed models spanning small molecule, peptide, and antibody modalities and serves more than five downstream a
This paper presents ARYA, a composable, physics-constrained, deterministic world model architecture built on five foundational principles: nano models, composability, causal reasoning, determinism, and architectural AI safety. We demonstrate that ARYA satisfies all canonical world model requirements, including state representation, dynamic prediction, causal and physical awareness, temporal consistency, generalization, learnability, and planning and control. Unlike monolithic foundation models, the ARYA foundation model implements these capabilities through a hierarchical system-of-system-of-systems of specialized nano models, orchestrated by AARA (ARYA Autonomous Research Agent), an always-on cognitive daemon that executes a continuous sense-decide-act-learn loop. The nano model architecture provides linear scaling, sparse activation, selective untraining, and sub-20-second training cycles, resolving the traditional tension between capability and computational efficiency. A central contribution is the Unfireable Safety Kernel: an architecturally immutable safety boundary that cannot be disabled or circumvented by any system component, including its own self-improvement engine. Thi
A policy-governed RAG architecture is specified for audit-ready generation in regulated workflows, organized as a triptych: (I) Contracts/Control (SHRDLU-like), which governs output adherence to legal and internal policies; (II) Manifests/Trails (Memex-like), which cryptographically anchors all cited source evidence to ensure verifiable provenance; and (III) Receipts/Verification (Xanadu-like), which provides the final, portable proof of compliance for auditors (portable COSE/JOSE) (see Section 4 and Appendix A). Rather than explaining model internals, outputs are gated ex-ante and bound to cryptographically verifiable evidence for each material answer. Unvalidated targets are stated (>=20% relative reduction in confident errors; p95 latency <= 900 ms; <= 2.2x serve cost) together with a pre-registered (optional) pilot using NO-GO gates. The design complements existing RAG/guardrails by making policy checks auditable, replayable, and receipt-backed. Target domains include back-office compliance in pharma, medical devices, finance, legal, and the public sector where error costs may exceed thousands of euros and audit trails are mandatory under regulations such as the EU AI
In 2008, melamine in infant formula forced laboratories across three continents to verify a compound they had never monitored. Non-targeted analysis using LC/GC-HRMS handles these cases. But when findings trigger regulatory action, reproducibility becomes operational: can an independent laboratory repeat the analysis and reach the same conclusion? We assessed 103 tools (2004-2025) against six pillars drawn from FAIR and BP4NTA principles: laboratory validation (C1), data availability (C2), code availability (C3), standardised formats (C4), knowledge integration (C5), and portable implementation (C6). Health contributed 51 tools, Pharma 31, and Chemistry 21. Nine in ten tools shared data (C2, 90/103, 87%). Fewer than four in ten supported portable implementations (C6, 40/103, 39%). Validation and portability rarely appeared together (C1+C6, 18/103, 17%). Over twenty-one years, openness climbed from 56% to 86% while operability dropped from 55% to 43%. No tool addressed food safety. Journal data-sharing policies increased what authors share but not what reviewers can run. Tools became easier to find but harder to execute. Strengthening C1, C4, and C6 would turn documented artifacts i
AI-powered LizAI XT ensures real-time and accurate mega-structure of different clinical datasets and largely inaccessible and fragmented sources, into one comprehensive table or any designated forms, based on diseases, clinical variables, and/or other defined parameters. We evaluate the platform's performance on a cluster of 4x NVIDIA A30 GPU 24GB, with 16 diseases -- from deathly cancer and COPD, to conventional ones -- ear infections, including a total 16,000 patients, $\sim$115,000 medical files, and $\sim$800 clinical variables. LizAI XT structures data from thousands of files into sets of variables for each disease in one file, achieving >95.0% overall accuracy, while providing exceptional outputs in complicated cases of cancers (99.1%), COPD (98.89%), and asthma (98.12%), without model-overfitting. Data retrieval is sub-second for a variable per patient with a minimal GPU power, which can significantly be improved on more powerful GPUs. LizAI XT uniquely enables fully client-controlled data, complying with strict data security and privacy regulations per region/nation. Our advances complement the existing EMR/EHR, AWS HealthLake, and Google Vertex AI platforms, for healthc
Lactose is widely used in agri-food and pharma industries. New materials that can be obtained from renewable sources are currently being sought. I have studied the effect of hydrostatic pressure on structural properties of currently known forms of crystalline lactose within the framework of density functional theory with van der Waals interactions. The computed parameters have good agreement with experimental data. The effect of mechanical deformations on electron structure of crystalline lactose was also studied. Compression of the crystal leads to the band gap increase. The analysis of partial density of states of lactose crystals was performed. The band gap of different forms of crystalline lactose was also computed using the quasiparticle G0W0 approximation.